Quick Answer
PharmaCyte Biotech, Inc. reported Operating Income of -$4.38 million for fiscal year 2025.
PharmaCyte Biotech, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$4.38M | +48.6% |
| 2024 | -$8.52M | -32.0% |
| 2023 | -$6.46M | -47.0% |
| 2022 | -$4.39M | -21.2% |
| 2021 | -$3.62M | +5.3% |
| 2020 | -$3.83M | +6.7% |
| 2019 | -$4.10M | +41.3% |
| 2018 | -$6.98M | -57.2% |
| 2017 | -$4.44M | +26.9% |
| 2016 | -$6.07M | +54.2% |
| 2015 | -$13.26M | +30.1% |
| 2014 | -$18.98M | -1026.8% |
| 2013 | -$1.68M | +13.6% |
| 2012 | -$1.95M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | -$2.12M | -120.6% | -53.9% |
| October 31, 2025 | -$1.38M | -24.4% | -62.2% |
| July 31, 2025 | -$848.3K | +33.1% | +11.7% |
| January 31, 2025 | -$960.3K | +48.6% | +13.2% |
| October 31, 2024 | -$1.11M | +21.5% | +12.8% |
| July 31, 2024 | -$1.27M | +38.9% | +32.1% |
| January 31, 2024 | -$1.87M | -20.3% | -32.6% |
| October 31, 2023 | -$1.41M | +39.2% | +32.1% |
- PharmaCyte Biotech, Inc. showed an increase of +48.6% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, PharmaCyte Biotech, Inc.’s operating income has declined by 124.6% (from -$1.95 million to -$4.38 million).
- The most recent figure is from PharmaCyte Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 11, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: